Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells

Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells

Activating mutations in KRAS are the hallmark genetic alterations in pancreatic ductal adenocarcinoma (PDAC) and the key drivers of its initiation and progression. Longstanding efforts to develop novel KRAS inhibitors have been based on the assumption that PDAC cells are addicted to activated KRAS,...

Full description

Bibliographic Details
Main Authors: Chen, Pan-Yu (Author), Muzumdar, Mandar (Author), Dorans, Kimberly (Author), Robbins, Rebecca (Author), Bhutkar, Arjun (Author), Del Rosario, Amanda M (Author), Mertins, Philipp (Author), Qiao, Jana (Author), Schafer, Anette Claudia (Author), Gertler, Frank (Author), Carr, Steven A (Author), Jacks, Tyler E (Author)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Broad Institute of MIT and Harvard (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: American Association for Cancer Research (AACR), 2020-03-30T15:10:30Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items